HRP20120416T1 - Postupci pripreme i uporabe smjesa kelata feri pirofosfat citrata - Google Patents
Postupci pripreme i uporabe smjesa kelata feri pirofosfat citrata Download PDFInfo
- Publication number
- HRP20120416T1 HRP20120416T1 HRP20120416AT HRP20120416T HRP20120416T1 HR P20120416 T1 HRP20120416 T1 HR P20120416T1 HR P20120416A T HRP20120416A T HR P20120416AT HR P20120416 T HRP20120416 T HR P20120416T HR P20120416 T1 HRP20120416 T1 HR P20120416T1
- Authority
- HR
- Croatia
- Prior art keywords
- ferric
- pyrophosphate
- citrate
- source
- amount
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 12
- 239000013522 chelant Substances 0.000 title claims abstract 11
- 229940036417 ferric pyrophosphate citrate Drugs 0.000 title claims abstract 9
- SXAWSYZURCZSDX-UHFFFAOYSA-B hydron;[hydroxy(oxido)phosphoryl] hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+);phosphonato phosphate Chemical compound [H+].[H+].[H+].[H+].[H+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OP([O-])(=O)OP(O)([O-])=O.OP([O-])(=O)OP(O)([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O SXAWSYZURCZSDX-UHFFFAOYSA-B 0.000 title claims abstract 9
- 238000000034 method Methods 0.000 title claims 14
- 238000002360 preparation method Methods 0.000 title claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims abstract 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract 9
- 239000010452 phosphate Substances 0.000 claims abstract 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 5
- 206010022971 Iron Deficiencies Diseases 0.000 claims abstract 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims 13
- 229910001447 ferric ion Inorganic materials 0.000 claims 13
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 9
- -1 citrate ions Chemical class 0.000 claims 8
- 235000011180 diphosphates Nutrition 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 5
- 239000008247 solid mixture Substances 0.000 claims 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 239000003960 organic solvent Substances 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 1
- PKDWUXLRYBKARO-UHFFFAOYSA-L 2-hydroxypropane-1,2,3-tricarboxylic acid;iron(2+);phosphono phosphate Chemical compound [Fe+2].OP(O)(=O)OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O PKDWUXLRYBKARO-UHFFFAOYSA-L 0.000 claims 1
- FPFSGDXIBUDDKZ-UHFFFAOYSA-N 3-decyl-2-hydroxycyclopent-2-en-1-one Chemical compound CCCCCCCCCCC1=C(O)C(=O)CC1 FPFSGDXIBUDDKZ-UHFFFAOYSA-N 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052787 antimony Inorganic materials 0.000 claims 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 claims 1
- 229910052785 arsenic Inorganic materials 0.000 claims 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims 1
- 229910052797 bismuth Inorganic materials 0.000 claims 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims 1
- 229910052793 cadmium Inorganic materials 0.000 claims 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 239000002526 disodium citrate Substances 0.000 claims 1
- 235000019262 disodium citrate Nutrition 0.000 claims 1
- 235000019820 disodium diphosphate Nutrition 0.000 claims 1
- GYQBBRRVRKFJRG-UHFFFAOYSA-L disodium pyrophosphate Chemical group [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 claims 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 claims 1
- VXWSFRMTBJZULV-UHFFFAOYSA-H iron(3+) sulfate hydrate Chemical compound O.[Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O VXWSFRMTBJZULV-UHFFFAOYSA-H 0.000 claims 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims 1
- 229910052753 mercury Inorganic materials 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229910052750 molybdenum Inorganic materials 0.000 claims 1
- 239000011733 molybdenum Substances 0.000 claims 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 claims 1
- 239000002524 monosodium citrate Substances 0.000 claims 1
- 235000018342 monosodium citrate Nutrition 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000006201 parenteral dosage form Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 claims 1
- 229910052716 thallium Inorganic materials 0.000 claims 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 claims 1
- 229910052718 tin Inorganic materials 0.000 claims 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
- 229940038773 trisodium citrate Drugs 0.000 claims 1
- 235000019263 trisodium citrate Nutrition 0.000 claims 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical class [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 235000007144 ferric diphosphate Nutrition 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Dental Preparations (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
U vodi topljiva čvrsta smjesa kelata feri pirofosfat citrata koja sadrži željezo citrat pirofosfat ifosfat u količini od ili manje težinski Patent sadrži još patentna zahtjeva
Claims (23)
1. U vodi topljiva čvrsta smjesa kelata feri-pirofosfat citrata koja sadrži:
željezo citrat pirofosfat; i
fosfat u količini od 2% ili manje, težinski.
2. Smjesa prema zahtjevu 1, gdje je željezo prisutno u količini od 7% do 11 % težinski, citrat je prisutan u količini od 14% do 30% težinski, i pirofosfat je prisutan u količini od 10% do 20% težinski.
3. Smjesa prema zahtjevu 1, koja je topljiva u vodi u količini od najmanje po mililitru vode.
4. Smjesa prema zahtjevu 1, gdje je fosfat prisutan u količini od 1.5% ili manje, težinski.
5. Smjesa prema zahtjevu 1, gdje je fosfat prisutan u količini od 1% ili manje, težinski.
6. Smjesa prema zahtjevu 1, gdje je fosfat prisutan u količini od 0.1% ili manje, težinski.
7. Postupak pripreme u vodi topljive čvrste smjese kelata feri-pirofosfat citrata koji obuhvaća:
spajanje izvora iona citrata, izvora iona pirofosfata i izvora feri iona u vodi radi dobivanja otopine;
dodavanje organskog otapala u volumenu koji je dovoljan za taloženje čvrste smjese kelata feri-pirofosfat citrata iz dobivene otopine; i
izoliranje čvrste smjese kelata feri-pirofosfat citrata, ta smjesa kelata sadrži 2% ili manje fosfata, težinski.
8. Postupak prema zahtjevu 7, gdje čvrsta smjesa kelata feri-pirofosfat citrata ima željezo prisutno u količini od 7% do 11% težinski, citrat je prisutan u količini od 14% do 30% težinski, i pirofosfat je prisutan u količini od 10% do 20% težinski.
9. Postupak prema zahtjevu 7, gdje su količine izvora iona citrata, izvora iona pirofosfata i izvora feri iona izabrane tako da molarni omjer feri ion: ion citrata: ion pirofosfata bude 0.9 do 1.1 : 0.9 do 1.1 : 0.45 do 0.55.
10. Postupak prema zahtjevu 7, gdje količina izvora iona citrata, izvora iona pirofosfata i izvora feri iona svaka sadrži manje od 250 mikrograma metala aluminija, antimona, arsena, bizmuta, kadmija, bakra, olova, žive, molibdena, talija i kositra po gramu izvora iona.
11. Postupak prema zahtjevu 7, gdje izvor iona pirofosfata sadrži manje od 0.1% fosfata.
12. Postupak prema zahtjevu 7, gdje izvor iona pirofosfata sadrži manje od 0.01% fosfata.
13. Postupak prema zahtjevu 7, gdje je količina vode za otapanje izvora iona citrata, izvora iona pirofosfata i izvora feri iona od 1.5 mililitara do 10 mililitara za svaki gram izvora feri iona.
14. Postupak prema zahtjevu 7, gdje se otopina zagrijava do temperature od do prije nego što se doda izvor feri iona i održava na temperaturi od do nakon što se doda izvor feri iona i dok ne dođe do potpunog otapanja izvora feri iona.
15. Postupak prema zahtjevu 14, gdje nakon što se izvor feri iona potpuno otopi, temperatura otopine se smanjuje do raspona od do radi hidrolize pirofosfata.
16. Postupak prema zahtjevu 7, gdje se organsko otapalo izabire između metanola, etanola, propanola, 2-propanola, acetonitrila, acetona, 2-butanona i kombinacija tih otapala.
17. Postupak prema zahtjevu 7, gdje se organsko otapalo dodaje u otopinu koja sadrži otopljeni izvor feri iona, otopljeni izvor iona citrata i otopljeni izvor iona pirofosfata u količini od 10 do 25 mililitara po gramu izvora feri iona.
18. Postupak prema zahtjevu 7, gdje se čvrsti kelat feri-pirofosfat citrata suši na temperaturi od ili nižoj.
19. Postupak prema zahtjevu 7, gdje se izvor feri iona izabire između feri sulfata, feri sulfat hidrata, feri klorida, feri amonij sulfata i kombinacija tih materijala;
izvor iona citrata se izabire između limunske kiseline, mononatrij citrata, dinatrij citrata, trinatrij citrata i kombinacija tih materijala; i
izvor iona pirofosfata se izabire između dinatrij dihidrogen pirofosfata, tetranatrij pirofosfata, i kombinacija oba ova materijala.
20. Farmaceutska smjesa koja sadrži oralni ili parenteralni dozirni oblik koji sadrži terapijski učinkovitu količinu čvrste smjese kelata feri-pirofosfat citrata s 2% ili manje fosfata, težinski.
21. Smjesa prema zahtjevu 20, koja je dijalizat.
22. Smjesa prema zahtjevu 20 ili 21 za uporabu u liječenju manjka željeza.
23. Smjesa za uporabu prema zahtjevu 22 gdje se liječenje odvija putem dijalize.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96132707P | 2007-07-20 | 2007-07-20 | |
| US12/138,018 US7816404B2 (en) | 2007-07-20 | 2008-06-12 | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120416T1 true HRP20120416T1 (hr) | 2012-07-31 |
Family
ID=40019183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120416AT HRP20120416T1 (hr) | 2007-07-20 | 2012-05-15 | Postupci pripreme i uporabe smjesa kelata feri pirofosfat citrata |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7816404B2 (hr) |
| EP (1) | EP2016940B1 (hr) |
| JP (1) | JP5489196B2 (hr) |
| AT (1) | ATE554754T1 (hr) |
| CY (1) | CY1113903T1 (hr) |
| DK (1) | DK2016940T3 (hr) |
| ES (1) | ES2383713T3 (hr) |
| HR (1) | HRP20120416T1 (hr) |
| PL (1) | PL2016940T3 (hr) |
| PT (1) | PT2016940E (hr) |
| SI (1) | SI2016940T1 (hr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090124572A1 (en) * | 2007-11-09 | 2009-05-14 | Deanna Jean Nelson | Iron-containing nutritional supplement |
| US9913806B2 (en) | 2008-06-25 | 2018-03-13 | Fe3 Medical, Inc. | Patches and methods for the transdermal delivery of a therapeutically effective amount of iron |
| RS52600B (en) * | 2008-09-29 | 2013-04-30 | Vifor (International) Ag | THE COURT AND PROCEEDINGS FOR THE STORAGE AND Bringing of Liquid and Liquid Medicinal Products |
| US8190252B2 (en) | 2009-02-12 | 2012-05-29 | Incube Labs, Llc | Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes |
| US8961492B2 (en) | 2009-02-12 | 2015-02-24 | Incube Labs, Llc | System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation |
| US8348922B2 (en) * | 2009-02-12 | 2013-01-08 | Incube Labs, Llc | Method and apparatus for oscillatory iontophoretic transdermal delivery of a therapeutic agent |
| US8821945B2 (en) | 2009-04-25 | 2014-09-02 | Fe3 Medical, Inc. | Method for transdermal iontophoretic delivery of chelated agents |
| US8417330B2 (en) * | 2009-06-26 | 2013-04-09 | Incube Labs, Llc | Corrosion resistant electrodes for iontophoretic transdermal delivery devices and methods of use |
| US8178709B2 (en) * | 2009-07-21 | 2012-05-15 | Biolink Life Sciences, Inc. | Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof |
| US8903485B2 (en) * | 2009-08-06 | 2014-12-02 | Incube Labs, Llc | Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes |
| US8685038B2 (en) | 2009-12-07 | 2014-04-01 | Incube Labs, Llc | Iontophoretic apparatus and method for marking of the skin |
| US8986279B2 (en) | 2010-02-10 | 2015-03-24 | Incube Labs, Llc | Methods and architecture for power optimization of iontophoretic transdermal drug delivery |
| EP2497380A1 (en) * | 2011-03-10 | 2012-09-12 | DSM IP Assets B.V. | Process for iron supplementation of beverages |
| CN106955415B (zh) | 2011-03-24 | 2019-06-18 | 因卡伯实验室有限责任公司 | 用于治疗剂的两阶段经皮离子电渗递送的系统及方法 |
| WO2012154704A2 (en) | 2011-05-06 | 2012-11-15 | Incube Labs, Llc | System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings |
| RU2472500C1 (ru) * | 2012-05-05 | 2013-01-20 | Илья Николаевич Медведев | Способ нормализации активности антитромбина iii в крови у новорожденных телят с железодефицитной анемией |
| BR112014027922A2 (pt) * | 2012-05-08 | 2017-06-27 | Dsm Ip Assets Bv | suplementação de sementes de arroz com ferro |
| CN107007624A (zh) * | 2013-02-01 | 2017-08-04 | 查拉克有限责任公司 | 用可溶性焦磷酸铁治疗铁缺乏症的方法 |
| PL3038475T3 (pl) * | 2013-08-28 | 2018-11-30 | Dsm Ip Assets B.V. | Suplementacja żelazem koncentratu bulionu |
| KR20160091918A (ko) | 2013-11-05 | 2016-08-03 | 락웰 메디컬, 인코포레이티드 | 저반응성 환자에서 에리스로포이에틴 자극제의 용량을 감소시키는 방법 |
| WO2015198304A1 (en) | 2014-06-22 | 2015-12-30 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
| JP5963185B1 (ja) * | 2015-04-13 | 2016-08-03 | 富田製薬株式会社 | ピロリン酸第二鉄含有粉末及びその製造方法 |
| EP3284717B1 (en) * | 2015-04-13 | 2019-10-30 | Tomita Pharmaceutical Co., Ltd. | Powder containing ferric pyrophosphate and method for producing same |
| SG10202107245UA (en) * | 2015-09-04 | 2021-08-30 | Rockwell Medical Inc | Solid soluble ferric pyrophosphate formulations, kits, and methods using the same |
| EP3153162A1 (en) | 2015-10-05 | 2017-04-12 | Navinta, llc. | Preparation of pharmaceutical dosage forms containing iron (iii) salts |
| JP2019501184A (ja) | 2016-01-06 | 2019-01-17 | ロックウェル メディカル，インコーポレイテッド | 鉄化合物及びシトレート化合物を用いる併用療法 |
| CN106977552B (zh) * | 2016-01-19 | 2019-11-05 | 山东诚创医药技术开发有限公司 | 枸橼酸焦磷酸铁混配络合物的制备方法 |
| JP6887598B2 (ja) * | 2016-07-21 | 2021-06-16 | 富田製薬株式会社 | 鉄含有飲食品 |
| CN106619494A (zh) * | 2016-10-10 | 2017-05-10 | 泰州海达医药科技有限公司 | 枸橼酸焦磷酸铁溶液及其制备方法 |
| ES2930013T3 (es) | 2017-03-31 | 2022-12-05 | Abbott Lab | Composiciones nutricionales líquidas que contienen aceite de pescado oxidable, ácido rosmarínico y hierro férrico |
| CN112159434A (zh) * | 2020-09-23 | 2021-01-01 | 北京沣瑞医药科技有限公司 | 枸橼酸焦磷酸铁配合物的制备方法 |
| CN112516163A (zh) * | 2020-12-21 | 2021-03-19 | 西安医学院 | 一种难溶性三价铁纳米脂质体复合物及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE579299A (hr) * | 1958-06-04 | |||
| US3275514A (en) * | 1960-04-12 | 1966-09-27 | Paul D Saltman | Process for introduction of metals into the mammalian system |
| US3259500A (en) * | 1961-10-11 | 1966-07-05 | Kentucky Res Foundation | Method for inhibiting anemia in young pigs by feeding the sow an iron agent |
| US3367834A (en) * | 1965-05-04 | 1968-02-06 | Dexter Martin | Method and compositions for enhancing the utilization of iron by mammals |
| AT279048B (de) * | 1967-07-04 | 1970-02-25 | Pharmazeutische Fabrik Montavit Gmbh | Verfahren zur Herstellung neuer, löslicher und stabiler organischer Eisen(III)-Komplexverbindungen und Injektionslösungen davon |
| US3686397A (en) * | 1970-05-18 | 1972-08-22 | Mueller Arthur | Parenteral iron preparations |
| SE359447B (hr) * | 1971-10-06 | 1973-09-03 | Astra Laekemedel Ab | |
| US4167564A (en) * | 1974-09-23 | 1979-09-11 | Albion Laboratories, Inc. | Biological assimilation of metals |
| US4058621A (en) * | 1975-02-24 | 1977-11-15 | Peter, Strong & Company, Inc. | Iron complexes and foodstuffs containing them |
| JPS5626709A (en) * | 1979-08-04 | 1981-03-14 | Nichia Kagaku Kogyo Kk | Manufacture of water soluble iron salt |
| EP0107458B1 (en) * | 1982-10-22 | 1987-07-29 | National Research Development Corporation | Pharmaceutical compositions |
| US5177068A (en) * | 1984-04-19 | 1993-01-05 | National Research Development Corporation | Pharmaceutical compositions |
| GB8713169D0 (en) * | 1987-06-05 | 1987-07-08 | Peters T J | Uptake of iron by body |
| CO4410161A1 (es) | 1994-02-28 | 1997-01-09 | Kellog Co | Producto de cereal listo para comer fortificado con complejo de edta ferrico y metodo para producirlo |
| CA2276442C (en) * | 1996-12-31 | 2012-01-17 | Ajay Gupta | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
| WO2001000204A1 (en) | 1999-06-30 | 2001-01-04 | Ajay Gupta | Method and pharmaceutical composition for parenteral administration of iron |
| US20030190355A1 (en) | 2002-04-05 | 2003-10-09 | Hermelin Marc S. | Modified release minerals |
| TWI335218B (en) * | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| US20060134227A1 (en) | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
| CA2634751C (en) * | 2005-12-23 | 2017-10-31 | Ajay Gupta | Parenteral nutrition composition containing iron |
-
2008
- 2008-06-12 US US12/138,018 patent/US7816404B2/en active Active
- 2008-07-08 PL PL08159949T patent/PL2016940T3/pl unknown
- 2008-07-08 DK DK08159949.0T patent/DK2016940T3/da active
- 2008-07-08 SI SI200830627T patent/SI2016940T1/sl unknown
- 2008-07-08 EP EP08159949A patent/EP2016940B1/en active Active
- 2008-07-08 PT PT08159949T patent/PT2016940E/pt unknown
- 2008-07-08 ES ES08159949T patent/ES2383713T3/es active Active
- 2008-07-08 AT AT08159949T patent/ATE554754T1/de active
- 2008-07-18 JP JP2008186771A patent/JP5489196B2/ja active Active
-
2012
- 2012-05-15 HR HRP20120416AT patent/HRP20120416T1/hr unknown
- 2012-07-23 CY CY20121100653T patent/CY1113903T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2016940B1 (en) | 2012-04-25 |
| ATE554754T1 (de) | 2012-05-15 |
| JP2009108027A (ja) | 2009-05-21 |
| US20090023686A1 (en) | 2009-01-22 |
| ES2383713T3 (es) | 2012-06-25 |
| CY1113903T1 (el) | 2016-07-27 |
| PT2016940E (pt) | 2012-07-12 |
| DK2016940T3 (da) | 2012-06-18 |
| JP5489196B2 (ja) | 2014-05-14 |
| SI2016940T1 (sl) | 2012-07-31 |
| PL2016940T3 (pl) | 2012-09-28 |
| US7816404B2 (en) | 2010-10-19 |
| EP2016940A1 (en) | 2009-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120416T1 (hr) | Postupci pripreme i uporabe smjesa kelata feri pirofosfat citrata | |
| McCann | The solubility of fluorapatite and its relationship to that of calcium fluoride | |
| US20070088161A1 (en) | Novel chelated bisphosphonates for use as pharmaceutical agents | |
| CN104071906B (zh) | 高效复合阻垢缓蚀剂 | |
| CN102127773B (zh) | 全无磷预清洗预膜药剂及清洗工艺 | |
| Chohan et al. | Transition metal acetylsalicylates and their anti-inflammatory activity | |
| JP2015110646A5 (hr) | ||
| CN107098832A (zh) | 一种和厚朴酚衍生物及其制备方法与应用 | |
| JPH01258693A (ja) | オキサアルカンポリホスホン酸ならびにそれを含む限界剤および錯化組成物 | |
| Cawthray et al. | In vivo study and thermodynamic investigation of two lanthanum complexes, La (dpp) 3 and La (XT), for the treatment of bone resorption disorders | |
| BR122019000367B1 (pt) | Processo para a inibição ou eliminação da formação de incrustações durante a produção de ácido fosfórico em um processo úmido | |
| CN104562031B (zh) | 一种预膜用组合物及预膜方法 | |
| CN111358991B (zh) | 一种鞋袜除臭抗菌组合物及其制备方法 | |
| CN112439396A (zh) | 羟基乙叉二膦酸/羟基磷灰石有机无机杂化复合材料及其制备方法 | |
| RU2017121659A (ru) | Комплекс фосфата цинка для ухода за полостью рта | |
| US20090221531A1 (en) | Novel phytic citrate compounds and process for preparing the same | |
| CA2638081A1 (en) | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions | |
| CN103450202B (zh) | L-5-甲基四氢叶酸与有机碱加成盐的方法 | |
| Cate et al. | Effect of impurities on density and viscosity of simulated wet-process phosphoric acid | |
| JP5591263B2 (ja) | ミネラル添加と酸処理を用いてメチオニンの溶解度を増加させる方法 | |
| JP6689052B2 (ja) | ２価カチオン低含有カラギーナン及びその製造方法 | |
| Skorik | D-Metal folates and the folic acid–imidazole conjugate | |
| Knobloch et al. | Inosylyl (3′→ 5′) inosine (IpI–). Acid–Base and Metal Ion-Binding Properties of a Dinucleoside Monophosphate in Aqueous Solution | |
| ITRM970195A1 (it) | Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio tartrato | |
| Moreno‐Luque et al. | Properties of the Magnesium (II) and Calcium (II) Complexes of 5‐and 6‐Uracilmethylphosphonate (5 Umpa2–and 6 Umpa2–) in Aqueous Solution |